<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Aim  Adjuvant <z:chebi fb="0" ids="46345">5-fluorouracil</z:chebi> based chemotherapy has demonstrated benefit in Stage III <z:hpo ids='HP_0003003'>colon cancer</z:hpo> but still remains controversial in Stage II </plain></SENT>
<SENT sid="1" pm="."><plain>The aim of this study was to analyse the prognostic impact of clinicopathological factors that may help guide treatment decisions in Stage II <z:hpo ids='HP_0003003'>colon cancer</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>Method  Between 1996 and 2006 data from patients diagnosed with <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> at Hospital Universitari Bellvitge and its referral comprehensive <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> centre Institut Català d'Oncologia/L'Hospitalet were prospectively included in a database </plain></SENT>
<SENT sid="3" pm="."><plain>We identified 432 patients with Stage II <z:hpo ids='HP_0003003'>colon cancer</z:hpo> operated on at Hospital Universitari Bellvitge </plain></SENT>
<SENT sid="4" pm="."><plain>The 5-year relapse-free survival (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RFS</z:e>) and <z:hpo ids='HP_0003003'>colon-cancer</z:hpo>-specific survival (CCSS) were determined </plain></SENT>
<SENT sid="5" pm="."><plain>Results  The 5-year <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RFS</z:e> and CCSS were 83% and 88%, respectively </plain></SENT>
<SENT sid="6" pm="."><plain>Lymphovascular or perineural invasion was associated with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RFS</z:e> [hazard ratio (HR) 1.84; 95% CI 1.01-3.35] </plain></SENT>
<SENT sid="7" pm="."><plain>Gender (women, HR 0.48; 95% CI 0.23-1) and lymphovascular or perineural invasion (HR 3.51; 95% CI 1.86-6.64) together with pT4 (HR 2.79; 95% CI 1.44-5.41) influenced CCSS </plain></SENT>
<SENT sid="8" pm="."><plain>In multivariate analysis pT4 and lymphovascular or perineural invasion remained significantly associated with CCSS </plain></SENT>
<SENT sid="9" pm="."><plain>We performed a risk index with these factors with prognostic impact </plain></SENT>
<SENT sid="10" pm="."><plain>Patients with pT4 <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumours</z:e> and lymphovascular or perineural invasion had a 5-year CCSS of 61%vs the 93% (HR 5.87; 95 CI 2.46-13.97) of those without any of these factors </plain></SENT>
<SENT sid="11" pm="."><plain>Conclusion  pT4 and lymphatic, venous or perineural invasion are confirmed as significant prognostic factors in Stage II <z:hpo ids='HP_0003003'>colon cancer</z:hpo> and should be taken into account in the clinical validation process of new molecular prognostic factors </plain></SENT>
</text></document>